1 2 3 4 5 6 7
читать далее ... Dancey J., Arnold A. et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin in patients as first-line therapy in patients with advanced non-small cell lung cancer: a study of National Cancer Institute of Canada clinical trials group. Cancer 2001, 92: 595-600 22. Koshi S., Herbst R., Obasaju C. Et al. A phase II trial of pemetrexed plus carboplatin in patients with advanced non-small-cell lung cancer. Proc. ASCO 2004, 23: 631 (abstr. 7074) 23. Scagliotti G., Kortsik C., dark G.G. et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized, phase II trial. Clin. Cancer Research 2005, 11:690-696 24. Adjei AA, Eriichman C, Sloan J et al. A phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent LY231514 (MTA) in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-1757 25. Ettinger D., Monnerat C., Kelly R. Et al. Phase II trial of pemetrexed plus gemcitabine in patients with advanced non-small-cell lung cancer: importance of survival over response. Proc. ASCO 2002, 21: 311a (abstr. 1243) 26. Treat J, Bonomi P, McCleod M. et all. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: A phase II trial. Lung Cancer. 2006 Jul;53(1 ):77-83 27. West H. J., Belt R. J., Wakele H. A., et all., Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. J Clin Oncol v.24 N 18S Part I of II, June 2006 [7116] 28. McCleod M., Treat J., Christiansen N. P., et all. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. J.CIin.Oncol. Vol 23, № 16S Part I and II. June 1,2005 [7121] 29. West H., Belt R. J., Wakelee HA, et all. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial J.CIin.Oncol. Vol 23, № 16S Part I and II. June 1, 2005 [7117] 30. Dudek A., Larson Т., McCleod M., et all. Initial results of a phase II study of biweekly pemetrexed and gemcitabine in patients with advanced NSCLC. J Clin Oncol v.24 N 18S Part I of II, June 2006 [7128] 31. Blakely J., Scnnell F., Kaywin P., et all. Phase II trial,of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol v.24 N 18S Part I of II, June 2006 [17031]Источник: Гуторов С.Л. Русский медицинский журнал. 2006. Т.14. №14. С.1032-1035